Amgen has more than 500 staff in the UK and Ireland, working in both the commercial and research & development organisations. The UK and Ireland commercial team operates out of our Cambridge and Dublin offices.
Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. At Amgen, we believe in a “biology first” approach. We use cutting-edge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases. Amgen believes the cure for disease can be found inside each and every one of us.
At AstraZeneca we have transformed our pipeline and returned to growth and, as a result of continued pipeline delivery and commercial execution, we are now entering a new stage of our journey. This is focused on enhanced innovation and the delivery of life-changing medicines that that contribute value to patients and society.
The fundamentals of our strategy are clear. We focus on innovative science and leadership in our three main therapy areas: Oncology; Cardiovascular, Renal and Metabolism; and Respiratory diseases. Backed by a global presence, with strength in Emerging Markets, particularly China, we have a portfolio of specialty and primary care medicines.
At the same time, the world around us is changing and the burden of disease is increasing. We are responding by increasing our focus on growth through innovation – being more patient-centric, doing more with technology, digital and data, and advancing more cutting-edge science.
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug manufacturing and digital health investment.
Eisai is one of the world’s leading research-based pharmaceutical companies. We define our corporate mission as “giving first thought to patients and their families, and to increasing the benefits health care provides,” which we call human health care (hhc). With operations in the U.S., Asia, Europe and it’s domestic home market of Japan, Eisai employs more than 11,000 people worldwide
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead’s portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
Our Pharmaceutical business has a broad portfolio of innovative and established medicines. We currently focus on developing new medicines in respiratory and HIV/infectious diseases, oncology and immuno-inflammation; with discovery research exploring these and other areas
In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now the second largest influenza vaccine company in the world. Cutting-edge facilities, technologies and technical expertise, Seqirus will be a reliable supplier of seasonal influenza vaccine with the ability to rapidly respond to pandemic threats
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.